Erasca, Corvus, and BioAge Target $500M+ Offerings Amid Biotech Fundraising Surge
Erasca is targeting $225 million through a public offering of 22 million shares at $10 each.
Erasca, Corvus, and BioAge are collectively seeking over $500 million in offerings, signaling renewed investor appetite in biotech.
These capital raises reflect improved market conditions for biotech equity offerings as reported on January 22, 2026.